View in EDS

Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.

Saved in:
Bibliographic Details
Title: Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Authors: Brown JR; The Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Eichhorst B; The Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany., Hillmen P; St. James's University Hospital, Leeds, United Kingdom., Jurczak W; Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland., Kaźmierczak M; The Department of Hematology & Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland., Lamanna N; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA., O'Brien SM; Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA., Tam CS; The Alfred Hospital & Monash University, Melbourne, VIC, Australia., Qiu L; The State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China., Zhou K; The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China., Simkovic M; The Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove, Czech Republic, & The First Faculty of Medicine, Charles University, Prague, & the Department of Internal Medicine, Prague, Czech Republic., Mayer J; Hematology & Oncology, Masaryk University & University Hospital, Brno, Czech Republic., Gillespie-Twardy A; Blue Ridge Cancer Care, Roanoke, Virginia, USA., Ferrajoli A; The Leukemia Department, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA., Ganly PS; The Department of Haematology, Christchurch Hospital, Christchurch, New Zealand., Weinkove R; Te Rerenga Ora Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, & the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand., Grosicki S; The Department of Hematology & Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland., Mital A; The Department of Hematology & Transplantology, Medical University of Gdańsk, Gdańsk, Poland., Robak T; The Medical University of Lodz, Lodz, Poland., Osterborg A; The Department of Oncology-Pathology, Karolinska Institutet, Stockholm & the Department of Hematology, Karolinska University Hospital, Stockholm, Sweden., Yimer HA; Texas Oncology-Tyler, US Oncology Network, Tyler, Texas, USA., Salmi T; BeiGene International GmbH, Basel, Switzerland., Wang MD; BeiGene USA, San Mateo, California, USA., Fu L; Formerly of BeiGene., Li J; BeiGene (Beijing), Beijing, China., Wu K; BeiGene USA, San Mateo, California, USA., Cohen A; BeiGene USA, San Mateo, California, USA., Shadman M; The Fred Hutchinson Cancer Center & the Department of Medicine, University of Washington, Seattle, USA.
Source: Future oncology (London, England) [Future Oncol] 2024 Apr; Vol. 20 (12), pp. 717-726. Date of Electronic Publication: 2023 Dec 13.
Publication Type: Patient Education Handout
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38088119
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Brown+JR%22">Brown JR</searchLink>; The Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Eichhorst+B%22">Eichhorst B</searchLink>; The Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Hillmen+P%22">Hillmen P</searchLink>; St. James's University Hospital, Leeds, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Jurczak+W%22">Jurczak W</searchLink>; Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland.<br /><searchLink fieldCode="AU" term="%22Kaźmierczak+M%22">Kaźmierczak M</searchLink>; The Department of Hematology & Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland.<br /><searchLink fieldCode="AU" term="%22Lamanna+N%22">Lamanna N</searchLink>; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York, USA.<br /><searchLink fieldCode="AU" term="%22O'Brien+SM%22">O'Brien SM</searchLink>; Chao Family Comprehensive Cancer Center, University of California, Irvine, California, USA.<br /><searchLink fieldCode="AU" term="%22Tam+CS%22">Tam CS</searchLink>; The Alfred Hospital & Monash University, Melbourne, VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Qiu+L%22">Qiu L</searchLink>; The State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.<br /><searchLink fieldCode="AU" term="%22Zhou+K%22">Zhou K</searchLink>; The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.<br /><searchLink fieldCode="AU" term="%22Simkovic+M%22">Simkovic M</searchLink>; The Fourth Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove, Czech Republic, & The First Faculty of Medicine, Charles University, Prague, & the Department of Internal Medicine, Prague, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Mayer+J%22">Mayer J</searchLink>; Hematology & Oncology, Masaryk University & University Hospital, Brno, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Gillespie-Twardy+A%22">Gillespie-Twardy A</searchLink>; Blue Ridge Cancer Care, Roanoke, Virginia, USA.<br /><searchLink fieldCode="AU" term="%22Ferrajoli+A%22">Ferrajoli A</searchLink>; The Leukemia Department, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Ganly+PS%22">Ganly PS</searchLink>; The Department of Haematology, Christchurch Hospital, Christchurch, New Zealand.<br /><searchLink fieldCode="AU" term="%22Weinkove+R%22">Weinkove R</searchLink>; Te Rerenga Ora Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, & the Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.<br /><searchLink fieldCode="AU" term="%22Grosicki+S%22">Grosicki S</searchLink>; The Department of Hematology & Cancer Prevention, Faculty of Health Sciences, Medical University of Silesia, Katowice, Poland.<br /><searchLink fieldCode="AU" term="%22Mital+A%22">Mital A</searchLink>; The Department of Hematology & Transplantology, Medical University of Gdańsk, Gdańsk, Poland.<br /><searchLink fieldCode="AU" term="%22Robak+T%22">Robak T</searchLink>; The Medical University of Lodz, Lodz, Poland.<br /><searchLink fieldCode="AU" term="%22Osterborg+A%22">Osterborg A</searchLink>; The Department of Oncology-Pathology, Karolinska Institutet, Stockholm & the Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.<br /><searchLink fieldCode="AU" term="%22Yimer+HA%22">Yimer HA</searchLink>; Texas Oncology-Tyler, US Oncology Network, Tyler, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Salmi+T%22">Salmi T</searchLink>; BeiGene International GmbH, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Wang+MD%22">Wang MD</searchLink>; BeiGene USA, San Mateo, California, USA.<br /><searchLink fieldCode="AU" term="%22Fu+L%22">Fu L</searchLink>; Formerly of BeiGene.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; BeiGene (Beijing), Beijing, China.<br /><searchLink fieldCode="AU" term="%22Wu+K%22">Wu K</searchLink>; BeiGene USA, San Mateo, California, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+A%22">Cohen A</searchLink>; BeiGene USA, San Mateo, California, USA.<br /><searchLink fieldCode="AU" term="%22Shadman+M%22">Shadman M</searchLink>; The Fred Hutchinson Cancer Center & the Department of Medicine, University of Washington, Seattle, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2024 Apr; Vol. 20 (12), pp. 717-726. <i>Date of Electronic Publication: </i>2023 Dec 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Patient Education Handout
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38088119
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2217/fon-2023-0849
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 717
    Titles:
      – TitleFull: Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brown JR
      – PersonEntity:
          Name:
            NameFull: Eichhorst B
      – PersonEntity:
          Name:
            NameFull: Hillmen P
      – PersonEntity:
          Name:
            NameFull: Jurczak W
      – PersonEntity:
          Name:
            NameFull: Kaźmierczak M
      – PersonEntity:
          Name:
            NameFull: Lamanna N
      – PersonEntity:
          Name:
            NameFull: O'Brien SM
      – PersonEntity:
          Name:
            NameFull: Tam CS
      – PersonEntity:
          Name:
            NameFull: Qiu L
      – PersonEntity:
          Name:
            NameFull: Zhou K
      – PersonEntity:
          Name:
            NameFull: Simkovic M
      – PersonEntity:
          Name:
            NameFull: Mayer J
      – PersonEntity:
          Name:
            NameFull: Gillespie-Twardy A
      – PersonEntity:
          Name:
            NameFull: Ferrajoli A
      – PersonEntity:
          Name:
            NameFull: Ganly PS
      – PersonEntity:
          Name:
            NameFull: Weinkove R
      – PersonEntity:
          Name:
            NameFull: Grosicki S
      – PersonEntity:
          Name:
            NameFull: Mital A
      – PersonEntity:
          Name:
            NameFull: Robak T
      – PersonEntity:
          Name:
            NameFull: Osterborg A
      – PersonEntity:
          Name:
            NameFull: Yimer HA
      – PersonEntity:
          Name:
            NameFull: Salmi T
      – PersonEntity:
          Name:
            NameFull: Wang MD
      – PersonEntity:
          Name:
            NameFull: Fu L
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: Wu K
      – PersonEntity:
          Name:
            NameFull: Cohen A
      – PersonEntity:
          Name:
            NameFull: Shadman M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2024 Apr
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1744-8301
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Future oncology (London, England)
              Type: main
ResultId 1